Treatment Courses for Hepatitis C

28 tablets
Course for 28 days
Twinvir - Course for 28 days
Ladipasvir 90 mg,
Sophosbuvir 400 mg
Incepta Pharmaceuticals
Free Shipping Wordwide
84 tablets
Course for 84 days
Twinvir - Course for 84 days
Ladipasvir 90 mg,
Sophosbuvir 400 mg
Incepta Pharmaceuticals
Free Shipping Wordwide
56 tablets
Course for 56 days
Twinvir - Course for 56 days
Ladipasvir 90 mg,
Sophosbuvir 400 mg
Incepta Pharmaceuticals
Free Shipping Wordwide
  • 1
  • 2
  • 3
  • 4

General Information

  • Name

    Twinvir ™ - combined antiviral agent.

  • Composition

    One Twinvir ™ tablet contains Ladipasvir 90 mg and Sophosbuvir 400 mg.

  • Indication

    The combination of Ledipasvir and Sofosbuvir is used for the treatment of hepatitis C of genotype 1, 4, 5 and 6 in adults.

  • Dosage Form

    28 tablets, film-coated.

  • Dosage and Administration

    Recommended dosage: one tablet (Ladipasvir 90 mg and Sofosbuvir 400 mg) is taken orally once a day. Recommended duration of treatment for patients without experience of negative response to therapy: 12 weeks. With experience of a negative response to therapy (without cirrhosis of the liver): 24 weeks. With experience of a negative response to therapy (with cirrhosis of the liver): 24 weeks.

  • Drug Interactions

    Joint use of the drug with amiodarone can lead to bradycardia. P-gp inductors (rifampicin, rifabutin, St. John's wort, carbmazepine, phenobarbital and phenytoin) lower the concentration of Ladipasvir and Sofosbuvir in the blood, which adversely affects the effectiveness of treatment.

  • Pregnancy and Lactation

    There is no data on the effect of the drug on fetal development and lactation. During pregnancy and breastfeeding, the drug can be prescribed only by the therapist.

  • Pediatrics

    The safety and efficacy of the combination of Ledipasvir and Sofosbuvir in patients under 18 years of age have not been studied.

  • Description

    Twinvir ™ is available in the form of tablets for oral administration. The composition includes two active components: Ladipasvir, which is an inhibitor of the viral protein, and also Sofosbuvir, an inhibitor of the RNA polymerase.

  • Special Instructions

    Bradycardia can occur in patients taking amiodarone, especially those who simultaneously use amiodarone with other drugs that slow the heart rate. The joint administration of amiodarone with the combination of Ledipasvir and Sofosbuvirais not recommended. Cardiac monitoring is recommended in patients without alternative treatment options. The dosage for patients with severe renal failure or renal insufficiency of the final stage is calculated individually by the attending physician. The use of Twinvir ™ with other drugs containing Sofosbuvir is not recommended.


What is Twinvir™?
Twinvir is a prescription drug consisting of two components: Ladipasvir and Sofosbuvir, intended for the treatment of hepatitis C genotypes 1, 4, 5 and 6 in adults.
Can Twinvir ™ be taken by HIV patients?
The combination of Ledipasvir and Sofosbuvir is possible for use in patients with hepatitis C and HIV. Before starting the treatment, you should consult your physician who will calculate the dosage individually.
How to take Twinvir™ correctly?
The drug should be taken as directed by your physician in accordance with the prescribed dosage. The dosage can be changed only by your physician. Twinvir ™ is taken the following way: one tablet once a day with or without food.
Is it necessary to take Twinvir ™ with other medicines to treat genotype 1, 4, 5, 6 of hepatitis C?
Usually, the use of additional medicines at the same time with Twinvir™ is not required. Depending on the severity of the disease and the associated pathologies, the physician can add Ribavirin to the course of treatment.
What side effects can occur when taking Twinvir™?
When treated with a combination of Ledipasvir and Sofosbuvir, side effects such as weakness and headache may occur.
What is the treatment duration with Twinvir™?
The treatment period is determined only by the attending physician. Depending on the condition of the patient with hepatitis C, Twinvir™ treatment may last 8, 12 or 24 weeks. In each case, the following factors should be considered: whether the person has previously been treated for hepatitis C, what the level of the virus in the body is, and also the degree of development of the liver disease (the presence or absence of cirrhosis) and whether liver transplantation has been performed.
What facts or conditions should the patient inform the physician of before taking Twinvir™?
Before taking this medication, the patient should notify the physician of the following:
  1. If there are other liver problems other than hepatitis C infection.
  2. If you have renal failure or you are on dialysis.
  3. If there are any other medical complications.
  4. If you are pregnant or you plan to conceive.
  5. If you are breastfeeding or you plan to.
It is not established whether the combination of Ledipasvir and Sofosbuvir penetrates into breast milk. Patients should inform the physician about all medications they take.
How to learn about the results of treatment with Twinvir ™ and to know whether there was a recovery?
The result of treatment with Twinvir™ can be determined three months after the beginning of the treatment. To find out if the patient has recovered from hepatitis C, a blood test is enough.
How should I store Twinvir™?
The drug is stored at room temperature, not exceeding 30 ° C..

Delivery system

You leave an order or call us
We pack the order and pass it to the courier service
Courier service will deliver your order within 5-8 days
You receive your order and pay it to the courier

How to order a course of treatment for hepatitis C?

You can order by calling us at the number:
+ 40 (31) 2295891

Call is free

or enter your phone and we will call you back

Enter your phone number:
Error! Enter your phone number
Error! Your message was not sent
Thank you! Wait for our manager to call.
Order via contact form:
Error! Enter your name
Error! Enter Email Address
Error! Enter your phone number
Error! Enter text
Error! You must agree to the terms and conditions
Error! Your message was not sent
Thank you! Your message has been sent, wait for the call of our manager.

About Us

  • Incepta Pharmaceuticals is a leading pharmaceutical company that was founded in 1999 in Bangladesh. We have large enterprises for the production of new drugs that are located in the territory of Savara and Dhamrai, located 35 and 53 kilometers from the center of the capital of Dhaka.
    We produce and issue almost all kinds of dosage forms: tablets, capsules, oral liquids, ampoules, bottles with dry powders, nasal sprays, suspension powders, eye drops, creams, ointments, lotions, gels, pre-filled syringes, lyophilized injections, vaccines etc.
    Since the foundation of our company, many new innovative products have been produced to meet the medical needs of the world community. The most important for us is the introduction of modern advanced technologies in medicine, their effectiveness and further development.

  • The main direction of Incepta Pharmaceuticals is the production and supply of high-tech and effective medicines. In our assortment there are the following kinds of dosage forms: sustained release tablets, quick dissolution tablets and effervescent tablets, sustained-release capsules, pre-filled syringes, insulin and its analogs, biological products and much more.
    On the territory of our enterprise we have modern pharmaceutical laboratory for research and development of the latest drugs, including inhalers with dry powder, pellets with coating, products with assisted release, medicines with disguised taste, etc.

  • Our experienced sales staff successfully promote pharmaceutical products throughout the country. We also develop supplies to villages and urban areas of Bangladesh. The company covers virtually every single corner of the countryside, including the urban areas of Bangladesh. Incepta Pharmaceuticals has created its own large distribution network, consisting of 21 warehouses throughout the country.
    Thanks to the developed strategy of our entry to the level of the leading research company for the production of dosage forms, Incepta Pharmaceuticals is successfully expanding its pharmaceutical activities. At present, we are supplying medicines of our own production to more than 60 different countries of the world. Thanks to hundreds of registered brands and the company's latest products under development, we are gradually strengthening our positions throughout all the continents.

  • The modern research laboratory of R&D company uses sophisticated advanced technologies to create new effective formulas based on studies previously unknown. Such activities not only benefit our company, but also the entire pharmaceutical sector. Soon we plan to officially launch the production of Active Pharmaceutical Ingredient (API).

  • In June 2011, Incepta Vaccines Limited, the subsidiary of Incepta Pharmaceuticals, established a modern enterprise in the Bangladesh market for the production and issue of vaccines for humans. Incepta is the first Bangladeshi company that acquired technology to create this kind of vaccine. Thanks to mass production, the company will be able to supply this product all over the world.

  • On January 15, 2011 Incepta introduced the world-famous ERP-SAP software system. Thus, we became the first Bangladeshi company to implement SAP for the management of medicinal resources. This system brought our daily activities to a new level, which allowed us to become more efficient in the production of drugs.

  • The company is constantly expanding its activities beyond the geographical boundaries of Bangladesh. We are open for cooperation with stakeholders in different countries. Incepta will continue to strive to provide high-quality medicine at affordable prices in Bangladesh and other parts of the world.

Quality Management System

Quality Management System (QMS)

  • QMS is designed to describe our activities in practice and in various documents. This system is based on the main principles of PIC/S and WHO. The company's charter describes the quality policy of Incepta Pharmaceuticals.

  • Technical responsibility is borne by the management department, which covers all activities necessary to create, maintain and verify the quality of our medicines.

  • Quality control of the Zirabo plant is carried out by qualified employees who have passed certification. Their main tasks and responsibilities are described in the quality manual and the corresponding SOP. The head of the control service, as well as his delegates are responsible for the release of medicinal substances, their form and packaging materials.

  • The quality department is responsible for IPC, compliance with GMP and training of personnel. Periodically, the control of compliance with all the standards at the workplace is carried out by analyzing the manufactured batch of the drug and inspecting the workplaces for contamination. The production lines and parameters of the equipment used are checked.

  • The immediate duty of our employees of the quality control department is to conduct external and internal audits among the staff, with subsequent monitoring of the effectiveness of the processes.

  • The research department is responsible for developing the formulation and new methods of treatment. The main task performed by the department is the systematic analysis and quality control of the products.

  • The charter of Incepta Pharmaceuticals company describes the instructions for production testing, the implementation, which is mandatory for maintaining a stable output of quality products.

  • Our company regularly conducts independent inspections for safety checks, compliance with hygiene standards and compliance with GMP, including documentation.

  • The supply of raw materials is carried out by approved and verified suppliers. Their selection takes place through evaluation and agreement, in accordance with rules and procedures from the charter. The same rules apply to the supply of primary and secondary packaging materials.

Change control procedure

  • Our team of quality control specialists, along with other relevant functions, is responsible for coordinating activities in all areas. Also, this department is responsible for bringing the changes made to the charter to the attention of all the parties involved.

  • The employees of the quality control department are responsible for the documentation, constant support and maintenance of all changes made to the charter.

  • The ventilation and air conditioning system serving the production and service areas is designed in accordance with the International Standard and meets all safety standards.

  • The company's charter contains the facility inspection plan. It describes the strategy covering the compliance of equipment with technical standards, production process and product quality checks, cleaning validation, personnel check, etc.

  • Staff training is a standard procedure in our company. The need for advanced training depends on the functions of the employee. Human Resources Department and a specialized group of inspectors reveals the expediency in training.

Quality assurance

With all responsibility, we GUARANTEE 100% no forgery, and here’s why:

  • All the production stages are carried out according to the European quality standards by R&D on their own equipment.

  • The warehouses on which Incepta Pharmaceuticals products are stored have a GDP certificate.

  • Transportation is carried out with observance of all the temperature mode rules and standards.

  • Ordering a course of treatment with us, you get the original drug only.